Alamar Biosciences, Inc.

Public Equity (Nasdaq Stock Market)ProteomicsBiotechPublic

📍 Fremont, CA, United States• Founded 2018

StreetZero Signal 71

Be the first to signal interest

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc. is a life sciences company founded in 2018 in Fremont, California, focused on ultra-high sensitivity protein analysis. Its proprietary NULISA Platform and ARGO HT System enable single-digit attomolar detection sensitivity for precision proteomics and early disease detection. The company has raised a total of $250M-$254M across multiple rounds and is now publicly listed on NASDAQ.

LATEST FUNDINGRule 144

$36.7M

Announced 2026-10-14

TOTAL RAISED$254M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Alamar Biosciences, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2018

HQFremont, CA, United States

Industry

Public Equity (Nasdaq Stock Market)

Investors

T. Rowe Price Sands Capital Qiming Venture Partners Illumina Ventures Pura Vida Investments

Key highlights

Raised $128M in Series C financing in January 2026 to accelerate platform commercialization.
Total funding reached $250M-$254M across four rounds since 2020.
NULISA platform achieves single-digit attomolar protein detection sensitivity.
Qiming Venture Partners held ~19.2% stake prior to NASDAQ listing.
Company listed on NASDAQ as a precision proteomics leader.

Ask StreetZero about Alamar Biosciences, Inc.

Put our AI to work on this deal.

What is Alamar Biosciences, Inc.'s value proposition?Who are Alamar Biosciences, Inc.'s competitors?Why does this raise matter?Summarize Alamar Biosciences, Inc. for an investor.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.